mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for PARP3
Gene summary
Basic gene Info.Gene symbolPARP3
Gene namepoly (ADP-ribose) polymerase family, member 3
SynonymsADPRT3|ADPRTL2|ADPRTL3|ARTD3|IRT1|PADPRT-3
CytomapUCSC genome browser: 3p21.31-p21.1
Type of geneprotein-coding
RefGenesNM_001003931.3,
NM_005485.5,NM_001003935.2,
DescriptionADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 2ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 3ADP-ribosyltransferase diphtheria toxin-like 3ADPRT-3NAD(+) ADP-ribosyltransferase 3NAD+ ADP-ribosyltransferase 3poly
Modification date20141207
dbXrefs MIM : 607726
HGNC : HGNC
Ensembl : ENSG00000041880
HPRD : 06370
Vega : OTTHUMG00000156931
ProteinUniProt: Q9Y6F1
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_PARP3
BioGPS: 10039
PathwayNCI Pathway Interaction Database: PARP3
KEGG: PARP3
REACTOME: PARP3
Pathway Commons: PARP3
ContextiHOP: PARP3
ligand binding site mutation search in PubMed: PARP3
UCL Cancer Institute: PARP3
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0006302double-strand break repair21270334
GO:0006471protein ADP-ribosylation21270334


Top
Ligand binding site mutations for PARP3
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
A416E418DUCEC1
V288L289MUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for PARP3
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
V288L289M-1.0065807
A416E418D-0.20541743
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for PARP3 from PDB

Top
Differential gene expression and gene-gene network for PARP3
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of PARP3 and the right PPI network was created from samples without mutations in the LBS of PARP3. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for PARP3
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for PARP3
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB076772-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-oneSmall molecule
ExperimentalDB080584-[3-(1,4-diazepan-1-ylcarbonyl)-4-fluorobenzyl]phthalazin-1(2H)-oneSmall molecule
ExperimentalDB08348N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDESmall molecule
ApprovedDB09074OlaparibSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of PARP3 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
P34N~2~,N~2~-DIMETHYL-N~1~-(6-OXO-5,6-DIHYDROPHENANTHRIDIN-2-YL)GLYCINAMIDE3ce0AA416
GAB3-AMINOBENZOIC ACID3fhbAA416
1DC3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL)-N-[(1S)-1- (PYRIDIN-4-YL)ETHYL]PROPANAMIDE4l6zAV288
1VDN-{(1S)-1-[4-(1H-IMIDAZOL-1-YL)PHENYL]ETHYL}-3-(4-OXO- 3,4-DIHYDROQUINAZOLIN-2-YL)PROPANAMIDE4l7oAV288
1VCMETHYL N-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-YL) PROPANOYL]-L-PHENYLALANINATE4l7uAV288 A416


Top
Conservation information for LBS of PARP3
Multiple alignments for Q9Y6F1 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas